PLATINUM-RESISTANT OVARIAN CANCER
Clinical trials for PLATINUM-RESISTANT OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT OVARIAN CANCER trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat ovarian cancer: Rina-S faces off against standard chemo in major trial
Disease control OngoingThis study tests a new drug called Rina-S against standard chemotherapy for people with ovarian cancer that has stopped responding to platinum-based treatments. About 530 participants will be randomly assigned to receive either Rina-S or one of four approved chemo drugs. The goal…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Drug combo shows promise in early ovarian cancer trial
Disease control OngoingThis early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Virus therapy takes on Platinum-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new approach for ovarian cancer that has stopped responding to platinum chemotherapy. It combines TILT-123, a virus engineered to kill cancer cells and boost immune activity, with the immunotherapy drug pembrolizumab, and in some cases also with a c…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for hard-to-treat ovarian cancer: drug duo enters phase 2 trial
Disease control OngoingThis study tests whether combining two immunotherapy drugs, ONC-392 and pembrolizumab, can shrink tumors in people with platinum-resistant ovarian cancer. About 58 adults with high-grade serous ovarian, primary peritoneal, or fallopian tube cancer are taking part. The goal is to …
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New combo aims to outsmart Platinum-Resistant ovarian cancer
Disease control OngoingThis study tests a new drug called NP-G2-044 (Prilukae) combined with standard chemotherapy (PLD) in people with ovarian cancer that no longer responds to platinum-based treatments. About 380 participants will receive either the combo or PLD alone to see if the combination improv…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE2, PHASE3 • Sponsor: Novita Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New immune drug shows promise in early trial for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC